Jiangsu Yahong Meditech Co., Ltd. (SHA:688176)

Market Cap	5.57B
Revenue (ttm)	238.34M
Net Income (ttm)	-384.75M
Shares Out	561.33M
EPS (ttm)	-0.68
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	59,681,186
Average Volume	10,644,283
Open	9.99
Previous Close	9.93
Day's Range	9.99 - 11.92
52-Week Range	4.71 - 11.71
Beta	0.67
RSI	65.94
Earnings Date	Aug 29, 2025

About Jiangsu Yahong Meditech

Jiangsu Yahong Meditech Co., Ltd., a pharmaceutical company, focuses on urogenital tumors and women's health in China and internationally. Its pipeline includes APL-1202, which is in Phase III clinical trial for the treatment of urinary system tumors; APL-1501, an oral MetAP inhibitor that is in Phase I clinical trial for the treatment of urinary system tumors; APL-1706, which is in Phase III clinical trial for the treatment of urinary system tumors; and APL-1702, a photodynamic therapy product that is in Phase III clinical trial for the treatm...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2010
• Employees: 391
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688176

Financial Performance

In 2024, Jiangsu Yahong Meditech's revenue was 201.56 million, an increase of 1365.55% compared to the previous year's 13.75 million. Losses were -384.06 million, -4.09% less than in 2023.